[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Anti-Dyslipidemia Products to Provide Alternatives to Statin Treatment, States GBI Research in Its Study Available at MarketPublishers.com

24 Nov 2016 • by Natalie Aster

LONDON – The treatments of cardiovascular disease (CVD) are mainly focusing on prevention by controlling certain risk factors of CVD. As such, the treatments fall within anti-hypertensives, anti-dyslipidemia drugs, and anti-thrombotic drugs.

Over the past few decades, there has been extensive scientific research and innovation across the CVD therapeutics marketplace, especially within the anti-dyslipidemia market with the emergence of statins like Lipitor, the top-selling drug of all time, which essentially reduces blood cholesterol levels. In the recent past, the frequently used direct factor Xa inhibitors which produce anticoagulant effects have begun to be administered orally and the emergence of PCSK9 inhibitors offers a viable alternative dyslipidemia therapy for dyslipidemia in case statins are inefficient or unsuitable. Currently, 1368 products are in the pipeline in the CVD market, with the most researched therapy field being thrombosis and 406 pipeline drugs being indicated for prevention or treatment of cardiovascular thrombotic events.

Amongst those pipeline drugs expected for oncoming release to market there is a blend of first-in-class drugs, generally anti-dyslipidemia products aimed at providing alternatives to statin treatment, and drugs belonging to the popular direct factor Xa inhibitors and PCSK9 inhibitors.

Insightful research report “Global Cardiovascular Disease Market to 2022” created by GBI Research offers a comprehensive guide to the marketplace, covering innovation in the CVD marketplace with respect to the overall pipeline and today’s market landscape; insights into the deals both licensing deals and co-development deals. The study offers a brief introduction to the disease; comprehensive review of the pipeline; comprehensive market forecasting to 2022; identification and evaluation of key pipeline products. The report identifies the top companies in the market, with respect to their growth and market share. Additionally, the report analyses the primary factors that will likely boost the market growth for the leading companies.

More new market research reports by our market research partner are available at its page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest